Abstracts tagged "osteoclasts and treatment"

Abstract Number: 2215 • 2015 ACR/ARHP Annual Meeting
Ticagrelor Regulates Osteoblast and Osteoclast Function and Promotes Bone Formation in Vivo By Increasing Adenosine Levels
Aranzazu Mediero¹, Tuere Wilder², Carl Whatling³ and Bruce Cronstein⁴, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, ³CVMD Innovative Medicine Unit, Translational Sciences, AstraZeneca R&D, Mölndal, Sweden, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY
Background/Purpose: The antiplatelet drugs Ticagrelor and clopidogrel are P2Y12 antagonists but ticagrelor also inhibits cellular adenosine uptake via ENT1 and thereby increases extracellular adenosine levels.…
Abstract Number: 24 • 2014 ACR/ARHP Annual Meeting
Netrin1 Is Highly Expressed and Required in Inflammatory Infiltrates in Wear Particle-Induced Osteolysis
Aranzazu Mediero¹, Bhama Ramkhelawon², Ed Purdue³, Steven R. Goldring⁴, Kathryn Moore² and Bruce N. Cronstein⁵, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, ³535 East 70th Street, Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Osteoclasts play a critical role in homeostatic bone turnover and pathologic bone destruction. Netrin-1, expressed in the marrow only by osteoclast precursors, acts in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].